Skip to main content
padlock icon - secure page this page is secure

Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy

Buy Article:

$52.00 + tax (Refund Policy)

Aim:  Hepatic steatosis is one of the factors limiting the virological response to interferon‐based antiviral therapy for chronic hepatitis C (CH‐C) patients infected with genotype 1, while contradictory results have been reported for genotype 2. We aimed to clarify the effect of hepatic steatosis on therapeutic outcome and cumulative positivity of serum HCV RNA in CH‐C patients infected with genotype 2 treated by peginterferon (PEG‐IFN)α2b and ribavirin (RBV) combination therapy.

Methods:  A total of 74 treatment‐na├»ve non‐cirrhotic CH‐C patients infected with genotype 2 who received PEG‐IFNα2b and RBV according to the standard regimen were divided into hepatic steatosis 0–10% and >10% groups. The clinical backgrounds, sustained virological response (SVR) rates and cumulative positivity of serum HCV RNA were compared between the two groups.

Results:  Among the 74 patients, 61 (82.4%) had hepatic steatosis 0–10% and 13 (17.6%) had hepatic steatosis >10%. Scores of homeostasis model assessment‐insulin resistance and hepatic fibrosis were higher in patients with hepatic steatosis >10% than hepatic steatosis 0–10% (P = 0.040 and 0.042, respectively). Non‐SVR was more frequent in patients with hepatic steatosis >10% than hepatic steatosis 0–10% (P = 0.003). Cumulative positivity of serum HCV RNA was significantly higher in patients with hepatic steatosis >10% than hepatic steatosis 0–10% (P = 0.004).

Conclusions:  In CH‐C patients infected with genotype 2 treated by PEG‐IFNα2b and RBV combination therapy, hepatic steatosis >10% was associated with increased insulin resistance, advanced hepatic fibrosis and higher cumulative positivity of serum HCV RNA, which lead to a higher risk of non‐SVR.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 2: Department of Gastroenterology, Matsushita Memorial Hospital 3: Department of Gastroenterology and Hepatology Nara City Hospital, Nara, Japan 4: Hepatology Center, Saiseikai Suita Hospital, Osaka

Publication date: December 1, 2011

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more